P302 Utility of 'trough levels' determination and anti-infliximab antibodies in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters (PK) through population pharmacokinetic model

MLA

G. Juan, et al. “P302 Utility of ‘Trough Levels’ Determination and Anti-Infliximab Antibodies in Patients with Inflammatory Bowel Disease. Estimation of Individual Pharmacokinetic Parameters (PK) through Population Pharmacokinetic Model.” Journal of Crohn’s and Colitis, vol. 8, Feb. 2014, p. S190. EBSCOhost, https://doi.org/10.1016/s1873-9946(14)60423-2.

APA

G. Juan, A. Alvariño, Joaquín Hinojosa, N. Cano, N. Maroto, L. Oltra, & I. Ferrer. (2014). P302 Utility of “trough levels” determination and anti-infliximab antibodies in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters (PK) through population pharmacokinetic model. Journal of Crohn’s and Colitis, 8, S190. https://doi.org/10.1016/s1873-9946(14)60423-2

Chicago

G. Juan, A. Alvariño, Joaquín Hinojosa, N. Cano, N. Maroto, L. Oltra, and I. Ferrer. 2014. “P302 Utility of ‘Trough Levels’ Determination and Anti-Infliximab Antibodies in Patients with Inflammatory Bowel Disease. Estimation of Individual Pharmacokinetic Parameters (PK) through Population Pharmacokinetic Model.” Journal of Crohn’s and Colitis 8 (February): S190. doi:10.1016/s1873-9946(14)60423-2.